Tired of being an “average” trader? Join ULTIMATE STOCK ALERTS (search them) today! You wont regret it once you lock in your first 57% winner thanks to them!
I think you need to look at SG&A and R&D, at least the SG&A will continue to grow pretty fast.
In any biotech with good ref, SG&A is greater than R&D. Looking at the FOLD statements, they will certainly be spending a more on SG&A than R&D within 2 Qs.
That burn rate will be $40M/Q. Before this yr is over, they will need to do another SO.
The current mkt cap is 800M, if they need 200M, that comes out to a 25% dilution later this yr.
The unfortunate truth of dev bios is that since they need access to capital to grow, and since they only have access to equity capital, as the stock prices decline, they become less attractive.
I can't believe the destruction in the dev biotech space. I was in FOLD a lot, was out for the big drop, back in from 7 to 10, and out since then.
I'd love to play again, I just can't justify it with the current climate for the group.
Who said firing is not writing? In addition writing CSR, they also writing the presentations, just like we saw yesterday. You will see more presentations/reports/news/submission and more often. Buy it and getting rich.
Sentiment: Strong Buy
The unfortunate thing with so many investors is they ride the most apparent news and don't look beyond to find out where companies revenue streams source from. FOLD to me is a great opportunity especially at these prices. They have the channels in place to make this thing go.
A strong majority of Migalastat potential sales will be in Europe so this bantering by the politicians here in the USA should have little affect on revenues from the product.
From what I know, the FDA wanted more info regarding digestive issues with the drug.
Yes the company has been quiet but I guess there's not much to say. If you put out a lot of press releases then investors say you're hyping. I'm just waiting, hoping for a good EU review.
Lot of insiders (officers) sold in early January. FOLD releases their forecast on Jan. 11 stating that Fabry regulatory update will be submitted in Qtr 1. IMO, company officials know that it will be in late Qtr 1 and sold while the stock was at $9.01. The sentiment is "why is it taking so long" (FDA asked for additional info back in early October). Seems like there is a problem with the update??? Any other opinion will be appreciated. Thanks!
Hey, billydbaseball. I have not been following FOLD for a while, but still have a small position in the stock. Can you tell me what happened to migalstat approval in the US? Now FOLD's management is not even talking about it. I just read the January 29th release by Crowley on FOLD's 2016 outlook, and there isn't a word about it. Ron
hiring is not writing. even big pharma has contractors do this work...seems like a bad management decision to hire at this point and this size company...
You just look at Amicus's home page, They are hiring 2 high level medical writers. Usually, this sized pharma, do not have any medical writers.
load up the great news is coming sooner!
Sentiment: Strong Buy
As I have mentioned before, biotechs are the most volatile stocks on the market. The allure of the big score attracts the gambling type of investor (myself included). This type of investor tends to use margin which leads to the big swings and I am fairly certain that the index (and FOLD) are getting spanked by margin call selling. Same for the rally we had early this year which I'm sure was aided by traders buying on margin.
Has there been any fundamental changes in FOLD or the industry? Only if you believe that the political jabs at big pharma and biotech will gain footing and actually affect pricing, which I don#$%$ election season and democrats always go after big pharma but when Trump spoke of drug pricing earlier this week, now you have both sides taking aim and that started this last leg down for the sector.
I keep it simple. Is it cheaper to give a patient drugs then put them in the hospital? My guess is most of the time the answer is yes and until that trend reverses, drugs are worth the money. Also quality of life adds value to these meds so one must factor that into pricing.
I added to my FOLD position 2 weeks ago at 6.90 and yesterday at 5.86. I plan on waiting this out and expect the company to be very valuable over the next few years.
The bios are getting slammed. I added at 6.90 a few weeks ago and today at 5.86. Once the presidential attacks on drug companies are finished, the bios will get hot again but no one can pick an exact bottom so you just have to strategically buy as the get hammered.
Do the math and you will see how much value these drugs provide as they keep so many out of hospitals and until those prices peak, drugs will remain a better option for insurance companies. JMHO